CD73+CD8+ T cells define a subset with anti-tumor potential in DLBCL patients

This study highlights CD73⁺CD8⁺ T cells as a unique functional subset with potential therapeutic relevance in DLBCL. Their reduced exhaustion and heightened cytotoxicity position them as promising targets for immunotherapy strategies. However, the dual role of CD73 in adenosine-mediated immunosuppression warrants further investigation to reconcile its pro-tumorigenic effects with the observed anti-tumor activity of CD73⁺CD8⁺ T cells. Our findings deepen the understanding of CD8⁺ T cell heterogeneity in DLBCL and emphasize the need for mechanistic studies to explore CD73's context-dependent functions.